Related Experiment Videos
Immunogenic effect of bacteriophage in patients subjected to phage therapy
A Kucharewicz-Krukowska1, S Slopek
1Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw.
Abstract:
Fifty seven cases of bacterial infections subjected to phage therapy were tested for a production of antibodies against the applied bacteriophages. Monoinfections confirmed in 40 patients were caused in majority of cases by pyogenic Staphylococci (29 cases) and rarely by Gram-negative bacteria: Klebsiella, Escherichia, Proteus and Pseudomonas (11 cases). Polyinfections caused by the above types of bacteria were recorded in 17 cases. The titer of neutralizing and hemagglutinating antibodies was determined before phage therapy, in the 10th day and in some cases in the 21st day of its course. The effect of natural and immune antibodies on the final result of therapy was analyzed.
Insights
This study investigated antibody production in patients undergoing phage therapy for bacterial infections. Results analyzed the impact of natural and immune antibodies on therapeutic outcomes, particularly for Staphylococcus infections.
Area of Science:
- Microbiology
- Immunology
- Infectious Diseases
Background:
- Bacterial infections pose significant health challenges, with antibiotic resistance necessitating alternative treatments.
- Bacteriophage therapy, using viruses that infect bacteria, is a promising alternative or adjunct to antibiotics.
- Understanding the host immune response, specifically antibody production, is crucial for optimizing phage therapy efficacy.
Purpose of the Study:
- To evaluate the production of antibodies against bacteriophages in patients receiving phage therapy.
- To analyze the correlation between antibody titers (neutralizing and hemagglutinating) and therapeutic outcomes.
- To determine the influence of pre-existing and therapy-induced antibodies on the success of phage therapy.
Main Methods:
- Studied 57 patients with bacterial infections treated with phage therapy.
- Identified causative agents, including Staphylococcus (pyogenic) and Gram-negative bacteria (Klebsiella, Escherichia, Proteus, Pseudomonas).
- Measured antibody titers at baseline, day 10, and day 21 of phage therapy.
Main Results:
- Antibody production against applied bacteriophages was observed in patients undergoing phage therapy.
- Analysis focused on monoinfections (Staphylococcus predominant) and polyinfections.
- The study explored the relationship between antibody levels and treatment effectiveness.
Conclusions:
- Host antibody response is a key factor to consider in phage therapy.
- Further research is needed to elucidate the precise role of antibodies in modulating phage therapy outcomes.
- Optimizing phage therapy may involve strategies to manage or enhance the host immune response.